Sodium Ascorbate
drugOn this page
Also known as Ascorbate de sodiumAscorbato de sodioAscorbic acid sodium saltCevalinE-301E301INS NO.301INS-301Sodium ascorbate component of moviprepSodium ascorbate component of plenvuSID144210873
Summary
Sodium Ascorbate (CHEMBL591665) is an approved small-molecule flour treatment agent; indicated across 5 conditions including anemia and iron deficiency anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 5 conditions
- Clinical trials: 2
- Chemistry: 198.11 Da · C6H7NaO6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL591665 |
| Name | Sodium Ascorbate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 23667548 |
| ChEBI | CHEBI:113451 |
| Molecular formula | C6H7NaO6 |
| Molecular weight | 198.11 |
| InChIKey | PPASLZSBLFJQEF-RXSVEWSESA-M |
SMILES: C([C@@H]([C@@H]1C(=C(C(=O)O1)O)[O-])O)O.[Na+]
IUPAC name: sodium (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2H-furan-3-olate
ChEBI definition: An organic sodium salt resulting from the replacement of the proton from the 3-hydroxy group of ascorbic acid by a sodium ion.
Pharmacological roles (ChEBI): flour treatment agent, coenzyme, reducing agent.
Other ChEBI roles (chemical / environmental): food antioxidant, plant metabolite, human metabolite, Daphnia magna metabolite.
Also known as: Ascorbate de sodium, Ascorbato de sodio, Ascorbic acid sodium salt, Cevalin, E-301, E301, INS NO.301, INS-301, Sodium ascorbate, Sodium ascorbate component of moviprep, Sodium ascorbate component of plenvu, SODIUM ASCORBATE
Patent coverage: 42,810 distinct patent families (102,001 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 101,983 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
| iron deficiency anemia | 4 | MONDO:0001356 | HP:0001891 |
| endometriosis | 2 | MONDO:0005133 | EFO:0001065 |
| ovarian cancer | 1 | MONDO:0008170 | MONDO:0008170 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00228319 | PHASE1/PHASE2 | COMPLETED | Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants |
| NCT04796636 | PHASE1 | UNKNOWN | High-dose Intravenous Vitamin C in Patients With Septic Shock |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: anemia, iron deficiency anemia